Life Science News

Medtronic plc (NYSE:MDT) today announced it received a warning letter from the U.S. Food and Drug Administration (FDA) on December 9 for the company's Northridge, California facility, the headquarters for its Diabetes Business . The warning letter was issued following an inspection that concluded in July 2021 related to recalls of the MiniMed™ 600 series insulin infusion pump, and a remote controller device for MiniMed™ 508 and Paradigm™ pumps.

The warning letter focuses on the inadequacy of specific medical device quality system requirements at the Northridge facility in the areas of risk assessment, corrective and preventive action, complaint handling, device recalls, and reporting of adverse events.

"We are committed to fully resolving all observations as effectively and quickly as possible. Nothing is more important to us than providing the highest quality products to people living with diabetes," said Sean Salmon , executive vice president and president of the Diabetes business at Medtronic.

To ensure the most effective response to the warning letter, Medtronic will apply resources from across the company and utilize external experts. The company is implementing a range of corrective actions and process improvements related to the observations, and will continue reviewing these actions with the FDA.

Medtronic is not recommending any action by patients or their healthcare providers as a result of this warning letter.

"Every day millions of people living with diabetes around the world rely on the innovations we deliver, and Medtronic remains deeply committed to ensuring their safety and well-being," said Salmon.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:




Pamela Reese

Ryan Weispfenning

Public Relations

Investor Relations

+1-818-576-3398

+1-763-505-4626

View original content: https://www.prnewswire.com/news-releases/medtronic-diabetes-receives-fda-warning-letter-301445170.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

MDT
Valor Resources

Valor Secures Additional Concessions in Highly Prospective Gold - Copper- Silver Region in Peru

Valor Resources Limited (“Valor” or the “Company”) is pleased to announce that it has applied for additional tenure in an area located approximately 30km northeast of the Picha Project. The eight new concessions cover an area of approximately 6,000 hectares or 60km2 . The new project, to be titled Charaque Project, lies along a regional northwest-southeast geological trend which encompasses several deposits, including the Arasi and Jessica Gold mines (owned by Aruntani), the El Cofre polymetallic mine (owned by CIEMSA), Barrick’s Austral-Challhuani gold project and other prospects and historical mine workings.